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A comparison of acute kindney injury (AKI) post-percutaneous coronary intervention (PCI)
prediction models is lacking. In this study, we aim to compare the National Cardiovascular Data Registry (NCDR) CathPCI score to the Mehran score in acute coronary syndrome
(ACS) vs non-ACS patients.
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Methods

We included patients who received PCI at our facility between July 2015 and December 2017.
We excluded patients without a pre- and/or post-PCI serum creatinine, patients on dialysis
at the time of PCI and patients with missing variables required to calculate the predictive
scoring model. The primary outcome of this study was AKI post-PCI. Performance of the
NCDR CathPCI score and the Mehran score were evaluated by comparing the area under the
receiver-operating characteristic curve (AUROC) for both scores.

Results

The analysis included 1,507 patients. In non-ACS patients, the Mehran score performed better than the NCDR CathPCI score with AUROC 0.75 and 0.68 respectively (p=0.014). When
categorized into 4 risk groups, a Mehran score ≥ 2 had a sensitivity of 86% and a Mehran
score of ≥ 3 had a specificity of 83% in non-ACS patients. In contrast, when the NCDR
CathPCI score was categorized into risk groups, it was not able to predict the risk of AKI
(p=0.78) with sensitivity of 0% for the intermediate and high risk group. In ACS patients,
the NCDR CathPCI score was superior in predicting the risk for AKI with AUROC 0.79 versus
0.74 (p=.019).

Conclusion

In predicting AKI post-PCI, the NCDR CathPCI score performed better in ACS populations,
and the Mehran score performed better in the non-ACS population.
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Introduction

Contrast-induced acute kidney injury (AKI) is a
common complication in patients undergoing
percutaneous coronary intervention (PCI) and
is known to be associated with increased mortality rates, worsening of chronic kidney disease
(CKD), prolonged hospital stays and signifi-

cantly higher healthcare costs.1-3 Even though
the risk of contrast-induced AKI is relatively
low in the general population, it is significantly
augmented in patients undergoing diagnostic
procedures for comorbid conditions such as
coronary artery disease (CAD). A recent literature review revealed that of all the hospitalized
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patients who develop AKI, 12% to 14% had a
procedure involving radiographic contrast.4,5
Multiple prediction models have been developed to predict the risk of AKI after PCI.
However, a direct comparison of the commonly used models is lacking. In addition,
the differential performance of these scores
in patients presenting with acute coronary
syndrome (ACS) versus those with non-acute
presentation has not been evaluated. Of all
the post-PCI AKI prediction models, the NCDR
CathPCI model has been validated by the largest research study to date.6-17 It was also validated internationally and demonstrated good
discrimination in the Japanese population.18
Another well validated model is the one developed by Mehran et al. The Mehran score is one
of the earliest derived scores and is the most
widely used tool to predict contrast induced
nephropathy (CIN) post-PCI.19,20 Although more
recent scores have been developed,8-17 the
Mehran score has superior clinical utility and
usability. Recently, Abellas et al. validated the
score in Europe and indicated good discrimination in five out of six subgroups (age >75 years,
diabetes mellitus (DM), CKD, ST-elevation
myocardial infarction (STEMI), Killip ≥2 and
PCI), demonstrating that the Mehran score
is applicable internationally and is still useful
more than 10 years since it was established.
Furthermore, the Mehran score was validated
in predicting CIN in acute myocardial infarction
(MI) patients.20-22 (Appendix A)
In this study, we aim to compare the performance of the NCDR CathPCI and Mehran
scoring systems in predicting AKI after PCI to
determine which of the two models delivers a
higher predictive value. We also sought to compare the performance of these scoring systems
in patients who present with ACS versus nonACS presentation.

Methods

Study Population

The NCDR CathPCI Registry is sponsored by
the American College of Cardiology (ACC) and
the Society for Cardiovascular Angiography
and Intervention (SCAI) and has been previously described.23,24 This registry contains data
on patient demographics, clinical presentation,
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procedures, treatments, outcomes and mortality. It is from this registry where we obtained
our data from. NCDR variable definitions can
be found at the ACC NCDR web site (http://
www.acc.org/ncdr/cathlab.htm).
For this study, we identified patients who received PCI at our institution between July 2015
and December 2017 (n=2,020). Excluded from
the study were patients without a pre- and/or
post-PCI serum creatinine (n=411, 20%), patients on dialysis at the time of PCI (n=35, 1.7%)
and patients with missing variables required to
calculate the predictive scoring models (n=67,
3.3%). The final cohort included 1,507 patients.

Definitions

The primary outcome tracked in this study was
AKI post-PCI using the change in creatinine
from pre-procedure level to peak level after
the procedure. AKI is defined using the Acute
Kidney Injury Network (AKIN) definition as an
absolute increase in serum creatinine ≥0.3 mg/
dl and a ≥1.5-fold increase in serum creatinine
from baseline.25 Urine output was not collected in the NCDR CathPCI Registry and was
not used as a measure for AKI in this study.
Baseline glomerular filtration rate (GFR) was
used to categorize patients as normal, mild
CKD, moderate CKD, or severe CKD. GFR in
mL/min per 1.73 m2 was calculated using the
Modification of Diet in Renal Disease (MDRD)
formula26 as 175 x serum creatinine - 1.154 x
age - 0.203 x 1.212 (if patient is black) x 0.742 (if
patient is female). We used the World Health
Organization (WHO) criteria for anemia: baseline hemoglobin <13 g/dl for males and <12 g/
dl for females.27 Hypotension in this study was
defined as a systolic blood pressure less than
90 mm Hg for more than 30 minutes and/or
cardiac index below 2.2 L/min/m2 secondary
to cardiac dysfunction and/or requirement of
parenteral inotropes/vasopressors or mechanical support including intra-aortic balloon pump
(IABP), extracorporeal circulation, ventricular
assist devices to maintain blood pressure and
cardiac index above the aforementioned levels.
The timing of IABP (before PCI, during PCI or
after PCI) and status (elective versus emergent) were not available and peri-procedure
IABP was used instead.
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Calculations of NCDR CathPCI Score
and the Mehran Score

The NCDR CathPCI score incorporates 11 variables: age, chronic kidney disease (CKD), prior
cerebrovascular disease (CVD), prior heart
failure (HF), CAD presentation (non-ACS and
ACS [unstable angina/non-ST-segment elevation, ST-segment elevation]), diabetes mellitus
(DM), hypertension (HTN), cardiac arrest on
presentation, anemia, IABP and cardiogenic
shock. The Mehran score incorporates eight
variables: hypotension, IABP, HF, age >75 years,
anemia, DM, contrast volume and renal dysfunction.6 (Tables 1 and 2)

Statistical Analysis

The baseline characteristics and outcomes
were summarized by frequency tabulation
and means with standard deviations as appropriate. A student’s t-test and chi-square test
were used to compare baseline characteristics between ACS and non-ACS patients. The
discriminative ability of the scoring systems
for predicting outcomes were evaluated by the
receiver-operator characteristic curve analysis.

tients developed AKI post-PCI, 63 (6.18 %) in
the ACS group and only 7 patients (1.44%) in
the non-ACS group. Baseline characteristics,
treatments and outcomes are further outlined
in Table 1.

Performance of CathPCI Score and
Mehran Score in the Non-ACS Group

In patients who did not present with ACS,
the Mehran score performed better than the
NCDR CathPCI score with AUROC 0.75 vs 0.68
respectively (p=0.014) (Figures 1 and 2). When
categorized into 4 risk groups as described in
the Methods section, the Mehran score ≥2 had
a sensitivity of 86% and a Mehran score of ≥3
had a specificity of 83% in non-ACS patients. In
contrast, when the NCDR CathPCI score was
categorized into risk groups, as described in
the Methods section, it was not able to predict
the risk of AKI (p=0.78) with sensitivity of 0%
for the intermediate and high risk group (i.e.,
none of the AKI patients were predicted based
on the risk category). (Tables 2 and 3)

Performance of CathPCI Score and
Mehran Score in the ACS Group

The area under the receiver-operating characteristic curve (AUROC) was calculated and
compared for both scores using the DeLong
test.28 The CathPCI score was categorized to 3
risk categories (low risk <30 points, intermediate risk 30–37 and high risk >37 points) based
on the original study by Tsai et al.29 The Mehran
score was categorized into 4 risk groups (low
risk <6 points, moderate risk 6–10 points, high
risk 11–15 points and very high risk >15) based on
the original study by Mehran et al.6 Estimates
of sensitivity, specificity, positive and negative predictive values were calculated for each
score. The comparison between risk groups for
each score was performed using the chi square
test. All statistical comparisons were twotailed with value <0.05 considered statistically
significant. The data analysis was performed by
using STATA version 13.0 (StataCorp, College
Station, TX).

In patients who presented with ACS, the NCDR
CathPCI score was superior to the Mehran
score in predicting the risk for AKI with AUROC 0.79 vs 0.74 (p=0.019). (Figure 2) When
categorized into risk groups, both models were
predictive of AKI risk (p<0.001 for both models). A Mehran score of ≥6 had 85% sensitivity
and 48% specificity. (Table 2) A CathPCI score
of ≥30 had a sensitivity of 52% and a specificity
of 87%. (Table 3)

Results

This study is the first one to compare the
CathPCI score and the Mehran score in the
same population. The incidence of AKI in our
population was 4.6%, which is lower than the
incidence in the CathPCI (7.33%) and Mehran

Of the 1,507 patients included in the study,
1,020 (67.77%) presented with ACS (the ACS
group); the rest did not present with ACS (the
non-ACS group). A total of 70 (4.64%) pa-

Discussion

In this study, we compared the performance
of the NCDR CathPCI score with the Mehran
score in predicting AKI post-PCI in 2 different
populations. The Mehran score was superior in
predicting AKI in the non-ACS group, whereas
the NCDR CathPCI score was superior in the
ACS group.
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Table 1. Patient characteristics in the ACS vs non-ACS groups.
Non-ACS (n=487)

ACS (n=1020)

p-Value

Age (years) – mean ± SD

71.59 ± 9.20

68.16 ± 11.78

<0.05

Gender, male – no.%

311 (63.86%)

613 (59.86%)

0.136

White – no.%

458 (94.05%)

954 (93.16%)

0.518

Black – no.%

29 (5.95%)

62 (6.05%)

0.939

Smoker – no.%

78 (16.02%)

282 (27.54%)

<0.05

Hypertension – no.%

471 (96.71%)

926 (90.43%)

<0.05

Dyslipidemia – no.%

449 (92.20%)

853 (83.30%)

<0.05

Prior Myocardial Infarction – no.%

178 (36.55%)

342 (33.40%)

0.228

Prior Heart Failure – no.%

127 (26.08%)

209 (20.41%)

<0.05

Prior PCI – no.%

259 (53.18%)

476 (46.48%)

<0.05

Prior CABG – no.%

115 (23.61%)

218 (21.29%)

0.308

Cerebrovascular Disease – no.%

134 (27.52%)

212 (20.70%)

<0.05

Peripheral Artery Disease – no.%

161 (33.06%)

192 (18.75%)

<0.05

Diabetes Mellitus – no.%

219 (44.97%)

443 (43.26%)

0.532

DEMOGRAPHICS

HISTORY & MEDICAL CONDITIONS

CLINICAL EVALUATION
Anginal Class within 2 weeks

<0.05

No symptoms – no.%

20 (4.11%)

1 (0.10%)

CCSI – no.%

13 (2.67%)

0

CCSII – no.%

75 (15.40%)

8 (0.78%)

CCSIII – no.%

379 (77.82%)

281 (27.47%)

CCS IV – no.%

0

733 (71.65%)

35 (7.19%)

148 (14.45%)

Heart Failure within 2 weeks – no.%
NYHA w/in 2 weeks – no.%

<0.05
<0.05

Class I – no.%

7 (20.00%)

80 (54.05%)

Class II – no.%

22 (62.86%)

26 (17.57%)

Class III – no.%

6 (17.14%)

38 (25.68%)

Class IV – no.%

0

4 (2.70%)

Cardiogenic Shock w/in 24 hours – no.%

1 (0.21%)

11 (1.07%)

0.075

Cardiac Arrest within 24 hours – no.%

2 (0.41%)

15 (1.46%)

0.069

283 (58.11%)

923 (90.14%)

<0.05

166.69 ± 84.82

168.42 ± 84.79

0.645

0

15 (1.46%)

<0.05

PCI PROCEDURE
Diagnostic caths w/ PCI – no.%
Contrast Volume (ml) – mean ± SD
IABP – no.%
PCI Status

<0.05

PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular
Society classification; NYHA = New York Heart Association Classification; IABP = intra-aortic balloon pump; LVEF = left
ventricular ejection fraction; CKD = chronic kidney disease

308

Nguyen et al. (2020) 1:5. https://doi.org/10.36518/2689-0216.1110

Table 1. Con’t.
Non-ACS (n=487)

ACS (n=1020)

Elective – no.%

470 (96.51%)

147 (14.36%)

Urgent – no.%

15 (3.08%)

705 (68.85%)

Emergent – no.%

2 (0.41%)

171 (16.70%)

0

1 (0.10%)

51.42 ± 12.43

47.81 ± 14.92

<0.05

Hemoglobin (g/dl) – mean ± SD

13.36 ± 1.65

13.02 ± 2.24

<0.05

Creatinine (ng/ml) – mean ± SD

1.02 ±0.29

1.05 ± 1.41

<0.66

Cardiogenic shock – no.%

2 (0.41%)

18 (1.76%)

<0.05

Heart Failure – no.%

5 (1.03%)

12 (1.17%)

0.803

Cerebrovascular Disease – no.%

1 (0.21%)

5 (0.49%)

0.414

0

4 (0.39%)

0.167

Bleed within 72hrs – no.%

3 (0.62%)

39 (3.81%)

<0.05

CABG – no.%

3 (0.62%)

12 (1.17)

0.308

Salvage – no.%
Pre-PCI LVEF – mean ± SD

p-Value

PRE-PROCEDURE LABS

POST-PROCEDURE EVENT

Dialysis – no.%

PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular
Society classification; NYHA = New York Heart Association Classification; IABP = intra-aortic balloon pump; LVEF = left
ventricular ejection fraction; CKD = chronic kidney disease

Table 2. Incidence of AKI in Mehran score categories.
Mehran AKI Risk Score
≤ 5 (low)

6-10 (moderate)

11-16 (high)

≥ 16 (very high)

p

Non-ACS

1 (0.51%)

3 (1.47%)

1 (1.22%)

2 (40.00%)

<0.001

ACS

9 (2.06%)

23 (6.48%)

24 (13.26%)

7 (14.89%)

<0.001

Total

10

26

25

9

AKI = acute kidney injury; ACS = acute coronary syndrome

Table 3. Incidence of AKI in CathPCI score categories.
CathPCI AKI Risk Score
< 30 (low)

30-37 (intermediate)

≥ 37 (high)

p

7 (1.49%)

0 (0%)

0 (0%)

0.87

ACS

30 (3.46%)

17 (19.77%)

16 (24.24%)

<0.001

Total

37

17

16

Non-ACS

AKI = acute kidney injury; ACS = acute coronary syndrome
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Figure 1. Comparison of the NCDR AKI model to the Mehran score in non-acute coronary syndrome group.
(13.1%) original studies, indicating that our
population is probably a lower risk population
than the ones included in the original studies by
Tsai et al. and Mehran et al.29 The difference in
the definitions of AKI Network criteria and CIN
likely contributes to the wide difference in the
incidence of AKI between our study and Mehran’s. We used the Acute Kidney Injury Network
definition for AKI, which has been adopted by
the broader medical community as a standard
definition.25
Our study is also the first to evaluate the performance of both of these predictive models
in ACS and non-ACS populations. In our study,
the CathPCI score was superior to the Mehran
score in ACS patients. However, the CathPCI did not perform as well in the non-ACS
population. Several factors may contribute to
this difference. First, the mechanism of AKI in
patients with ACS is not limited to CIN. AKI in
ACS patients is multifactorial and is currently
believed to be a type of cardiorenal syndrome.29
Thus, the CathPCI score, which relies on many
factors that are related to hemodynamic stability, was superior to Mehran score in the prediction of AKI. On the other hand, the Mehran
score was developed originally to predict CIN,
which is likely the dominant etiology of AKI in
non-ACS patients. Therefore, the Mehran score
310

fared better in predicting outcomes in nonACS patients. Secondly, most of the patients in
the CathPCI derivation cohort23 presented with
ACS (71.1%); whereas, in the Mehran cohort,
ACS represented only 35.7% of the population.
This outcome may explain the superiority of
the Mehran score in the non-ACS subgroup and
the NCDR CathPCI score in the ACS subgroup.
(Figures 1 and 2)
This study has obvious practical clinical implications. The identification of the best prediction
model for different populations helps improve
the accuracy of the prediction and, thus, identifies high risk patients who otherwise would
have been undetected. For example, the CathPCI did not predict any of the patients with AKI
in the non-ACS group.

Study Limitations

Firstly, this study is retrospective. However, the data was collected prospectively by
trained staff according to predefined criteria.
The results were based on data from a single
institution with a relatively small sample size. In
addition, the registry lacks blood pressure measurements, and hypotension was considered
when patients developed cardiogenic shock, as
defined in the Methods section, within 24 hours
of presentation and/or IABP was required for
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Figure 2. Comparison of the NCDR AKI model to the Mehran score in acute coronary syndrome
group.
blood pressure support. Nevertheless, we believe these slight variations did not affect the
validity of the calculation of the scores.

the official views of HCA Healthcare or any of
its affiliated entities.

Conclusion

1.

NCDR CathPCI score performed better in the
ACS population, and the Mehran score performed better in the non-ACS population in
predicting AKI post-PCI. Given the aforementioned results, we suggest using the NCDR
CathPCI score to predict AKI in the ACS
patients, and the Mehran score for non-ACS
patients. We can better predict AKI post-PCI
using the appropriate score for the specific
clinical presentation.
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Appendix A

Predictive Scoring Systems for Predicting Acute Kidney Injury
Table A1. Mehran Score for calculating risk of
AKI.
Risk Factors

Integer Score

Hypotension

5

IABP

5

CHF

5

Age > 75 years

4

Anemia

3

Diabetes

3

Contrast media volume
Serum creatinine > 1.5 mg/dl
OR
eGFR < 60 ml/min/1.73 m3

1 for each 100 cc3
4
2 for 40–60
4 for 20–40
6 for <20

314

Table A2. CathPCI AKI score for calculating
risk of AKI.
Risk Factors

Integer Score

Age (years)
<50

0

50 – 59

2

60 – 69

4

70 – 79

5

80 – 89

8

>90

10

Priors weeks HF

11

Severe GFR (<30)

18

Moderate GFR (30–45)

8

Mild GFR (45–60)

3

Diabetes

7

Prior HF

4

Prior CVD

4

NSTEMI/UA

6

STEMI

15

Prior cardiogenic shock

16

